Article Sidebar
DOI:
10.4314/tjpr.v14i3.6Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
siRNAs Targeting Viral Protein 5: The Major Capsid Protein of Herpes Simplex Virus-1 Affects its Propagation and Cytoskeleton
Abstract
Purpose: To investigate whether siRNA targeting viral protein 5 (VP5) can become a new treatment for herpes simplex virus type 1 (HSV-1).
Methods: Flow cytometry was performed to determine the ratio of siRNA and lipo2000 to reach the highest transfection efficiency. Western blot and q-PCR were performed to determine the knockdown efficiency of siRNA targeting UL19, as well as changes in cytoskeleton proteins. Plaque reduction assays and confocal microscopy were conducted to test the influence of VP5 knockdown on the HSV-1 life cycle and viral replication. F-actin organization was observed through confocal microscopy during HSV-1 infection when transfected with siRNA.
Results: Relative expression level of the UL19 gene dropped to 6 % while plaque formation inhibition rate rose to 85 % compared with virus control. Knocking down VP5 expression abrogated the changes to F-actin that were induced by HSV-1 infection.
Conclusion: Interfering with UL19 gene expression inhibits HSV-1 replication efficiently in vitro. The results indicate that the major capsid protein VP5 encoding gene UL19 may be a promising target for RNA interference-based therapeutic strategy against HSV-1.
Keywords: siRNA, Viral protein 5, Herpes simplex virus type 1, Gene expression, Propagation, Cytoskeleton rearrangement, F-actin, Transfection
